Phase 3 Stomach Cancer Trial, Recruiting NCT04214990 Sponsor: National Cancer Center, Korea Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT04214990
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men and women between the ages of 19 and 70 years old
  • People who have had a procedure (done through a camera scope) to remove a high-grade pre-cancerous growth or early stomach cancer
  • People whose tissue results after the removal procedure met specific medical guidelines confirming the procedure was considered fully successful (confirm with trial site)
  • People who either never had a stomach bacteria infection called H. pylori, or who have already been treated and cleared of it
  • People who are willing to read and sign a consent form agreeing to take part

Who may not be able to join:

  • People who take aspirin regularly to prevent heart attacks or strokes
  • People who have taken aspirin more than 3 times a week in the 2 months before joining the trial
  • People who use blood thinners or anti-clotting medications for a medical condition
  • People who have previously had part or all of their stomach surgically removed
  • People currently being treated for a serious health condition such as severe heart problems, liver cirrhosis, kidney failure, serious lung disease, or an uncontrolled infection
  • People at high risk of bleeding complications, such as those with a brain aneurysm, abnormal blood vessels, varicose veins in the esophagus or stomach, or a blood clotting disorder like hemophilia
  • People with an active stomach or intestinal ulcer (people who have fully recovered from an ulcer may still be eligible)
  • People who have been diagnosed with and are actively being treated for another type of cancer within the past 5 years (certain very early-stage or skin cancers may be exceptions — confirm with trial site)
  • People whose stomach cancer removal procedure was not considered fully successful or complete
  • People who are allergic to aspirin or have a medical reason they cannot take it
  • Women who are pregnant or breastfeeding
  • People with alcohol dependency or drug abuse issues
  • People considered unsuitable for the trial by the study doctor
  • People who are unable or unwilling to sign the consent form
  • People who took less than 80% of a required trial medication during an initial 28-day test period before the study begins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Il Ju Choi, M.D., Ph.D., National Cancer Center, Korea

Phone: +82-31-920-2282

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
National Cancer Center, Korea
Registry
ClinicalTrials.gov
Start date
15 February 2020
Est. completion
31 March 2031

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

The incidence of gastric cancer between the intervention and placebo groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov